LUSPARANCT07331818
Luspatercept in Patients Affected With Rare Inherited Anemias
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Recruitment opened Show 4 more changesShow less
- Eligibility criteria expanded, about 35 words
- Start date changed from estimate of Jan 15, 2026 to Mar 17, 2026
- Secondary endpoints: details revised at 6 of 8 entries
- Site details revised at 6 of 6 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Evaluating Luspatercept in patients affected with rare inherited anemias - Transfusion dependent patients
Timeframe: Up to 52 weeks
Evaluating Luspatercept in patients affected with rare inherited anemias - Non Transfusion dependent patients
Timeframe: Up to 52 weeks
Secondary (8)
Proportion of Transfusion dependent patients with a reduction in the transfusion burden (33 % / week 13 - 24)
Proportion of Transfusion dependent patients with a reduction in the transfusion burden (50% / week 13 - 24)
Proportion of Transfusion dependent patients with a reduction in the transfusion burden (33 % / week 37 - 48)
Proportion of Transfusion dependent patients with a reduction in the transfusion burden (50 % / week 37 - 48)
mean change from baseline in the transfusion burden
Show 3 moreShow less
Proportion of Non Transfusion dependent patients - hemoglobin concentration
Proportion of Non Transfusion dependent patients - hemoglobin concentration increase
Proportion of Non Transfusion dependent patients - duration of mean hemoglobin concentration
Arms and interventions
LUSPATERCEPTExperimental
All eligible subjects will receive a starting dose of luspatercept of 1 mg/kg on day 1 of each 21 day cycle (every three weeks) In transfused patients, the first dose will be done at D8 from previous transfusion Responders at any dose will continue at the same dose until week 52 if they tolerate the drug (a follow up study will be envisaged)
Drugs: Reblozyl
Sites
6 sites in 2 countries
France 5, Italy 1